GrahamB wrote: Camphikefish wrote: While we wait. I had a brief conference with my investment advisor today and he questioned why I'd be invested in a biotech penny stock for over 10 years when my money could've tripled in the overall market. Of course I mentioned our unique science, efficacy, patient population, BTD, and the whole 9 yards as we say in the states. He briefly made me feel as if I must be financially immature, poorly informed, and misguided. There is no overall point here I'm mostly just sharing the empty pit I felt in my stomach for a minute. I wonder if any of you have felt the same? I told him we'd see who has the last laugh. Hopefully I've not been living in fantasyland for over a decade! I still believe we get to at least $5-10 eventually. Getting older! Let's go 1433 and take us to the finish line!
Financial advisors tend to be a conservative lot, and because penny stocks have significant risks
as they are story stocks. Sure, they could double, go 10x or more. The problem is they usually dont and are considered highly speculative, volatile, less liquid and the companies are usually unproven companies, and may have less rigorous reporting standards.
FWIW I did do a quick dive on this before and passed, and continue to follow.
If you look specifically at the financials for Theralase:
From the MRQ Financials: Total current assets 1,705,119 vs Total current liabilities 978,674
Sales of 218,926 With losses of (1,155,234) and negative 6 month cash flows (2,564,187)
Also, The company says under the going concern statement: “the Company’s existing product line have not met expectations and have not been sufficient inand of themselves to enable the Company to fund all its continuing development and commercialization efforts accordingly the Company will require additional capital to continue to research and develop its drug technology and market its device products as it continues to develop sales opportunities” so its dependent on finacings and dilution.
Source:
https://theralase.com/wp-content/uploads/2023/08/Q223-Financial-Statements-Final.pdf So if you put this together, Not sure about what the advisors specific comments were, your situtation, nor on the return quoted, but suppose directionally, the opportunity cost at this point certainly favors the advisor.
The story here with is interesting, but the risks are high re liquidity issues, increasing competition, and ongoing dilution.
But hey to each his, her, their own.
This one is not for me,but do your own due diligence and while its interesting to hear what others say-I wouldn’t trust what any poster says for my investment decision, especially me! Ha ha